Leukemia

Oncology 1 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Oncology indication. Leukemia has 1 FDA-approved novel treatment, led by Sanofi across 3 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Leukemia Market Leaders

Companies with the most FDA-approved novel Leukemia drugs.

Sanofi

original drugs

Phase 3 Readouts Pro

7 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q1 2027

QTX-2101 + ATRA

Quetzal Therapeutics

Estimated · fresh NCT07504458

Q2 2027

Pelabresib

Novartis

Estimated · stale NCT06401356

Q2 2027

Oral ATO

SDK Therapeutics, Inc.

Estimated · fresh NCT07296445

Unlock 4 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Leukemia Treatments by Mechanism

Top 12 mechanisms across 60 industry trials with a known mechanism of action.

See full pipeline →

Kinase Inhibitor

14 trials 6 active 9 sponsors

Nucleoside Metabolic Inhibitor

17 trials 3 active 10 sponsors

Menin Inhibitor

3 trials 3 active 1 sponsor

CD20-directed Cytolytic Antibody

6 trials 2 sponsors

DNA

5 trials 3 sponsors

ABL kinase/BCR-ABL/EPHA2/FYN/LCK/PDGFRβ/SRC/YES/c-KIT

4 trials 1 sponsor

Thalidomide Analog

3 trials 1 sponsor

Alkylating Drug

2 trials 1 sponsor

BCL-2 Inhibitor

2 trials 2 sponsors

HDAC

2 trials 1 sponsor

CD19/CD3

1 trials 1 sponsor

Purine Antimetabolite

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Leukemia Clinical Pipeline by Phase

430 industry-sponsored trials across 199 sponsors

Showing 8 of 8 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novartis	Asciminib single agent	—	RECRUITING	2030-08-30	NCT04877522
Pharmacyclics Switzerland GmbH	Ibrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-05-10	NCT03229200
Johnson & Johnson Private Limited	Ibrutinib 420 mg	—	COMPLETED	2023-05-03	NCT03190330
Pfizer	inotuzumab ozogamicin-dose level 2	—	COMPLETED	2022-09-21	NCT03677596
MP Biomedicals, LLC	—	—	COMPLETED	2018-07-10	NCT03226119
Roche	bendamustine	—	COMPLETED	2014-03	NCT01056510
Roche	Cyclophosphamide	DNA	TERMINATED	2016-05-04	NCT01271010
Roche	Chlorambucil	Alkylating Drug [EPC]	TERMINATED	2016-03-16	NCT01283386

Showing 50 of 50 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Quetzal Therapeutics	QTX-2101 + ATRA	—	RECRUITING	2027-03	NCT07504458
Novartis	Pelabresib	—	RECRUITING	2027-06-02	NCT06401356
Loxo Oncology, Inc.	Pirtobrutinib	Kinase Inhibitor [EPC]	RECRUITING	2027-10	NCT05254743
Taiho Oncology, Inc.	Azacitidine	Nucleoside Metabolic Inhibitor [EPC]	RECRUITING	2027-11-01	NCT04256317
Sunshine Lake Pharma Co., Ltd.	Clifutinib	—	RECRUITING	2027-11-30	NCT05586074
Ascentage Pharma Group Inc.	Olverembatinib	—	RECRUITING	2027-12-31	NCT06051409
Johnson & Johnson	Bleximenib	—	RECRUITING	2029-06-22	NCT06852222
Daiichi Sankyo	Quizartinib	—	RECRUITING	2030-06-26	NCT06578247
Merck	Nemtabrutinib	—	RECRUITING	2032-06-01	NCT05947851
Otsuka Australia Pharmaceutical Pty Ltd	Subcutaneous azacitidine	—	ACTIVE NOT RECRUITING	2024-12-06	NCT05883956
Orca Biosystems, Inc.	Orca-T	—	ACTIVE NOT RECRUITING	2024-07-15	NCT05316701
Actinium Pharmaceuticals	Iomab-B	—	ACTIVE NOT RECRUITING	2022-06	NCT02665065
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2021-02-26	NCT03462719
SDK Therapeutics, Inc.	Oral ATO	—	NOT YET RECRUITING	2027-06	NCT07296445
Actinium Pharmaceuticals	131I-apamistamab	—	NOT YET RECRUITING	2029-02	NCT07157514
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Nelarabine injection	—	NOT YET RECRUITING	2025-12	NCT06434467
Pfizer	Glasdegib	—	COMPLETED	2022-12-02	NCT04842604
Jazz Pharmaceuticals	IM JZP-458	—	COMPLETED	2022-07-13	NCT04145531
Astex Pharmaceuticals, Inc.	ASTX727	—	COMPLETED	2021-09-10	NCT03306264
Daiichi Sankyo	Chemotherapy	—	COMPLETED	2021-08-13	NCT02668653
Takeda	Azacitidine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2021-05-28	NCT03268954
Gamida Cell ltd	NiCord® (omidubicel)	—	COMPLETED	2021-04-29	NCT02730299
Pfizer	glasdegib	—	COMPLETED	2020-06-05	NCT03416179
Astex Pharmaceuticals, Inc.	Guadecitabine	—	COMPLETED	2020-03-31	NCT02907359
Bristol-Myers Squibb	AG-221	—	COMPLETED	2020-03-17	NCT02577406
Amgen	Blinatumomab	CD19/CD3	COMPLETED	2019-07-17	NCT02393859
Bristol-Myers Squibb	Oral Azacitidine	—	COMPLETED	2019-07-15	NCT01757535
Traws Pharma, Inc.	ON 01910.Na	—	COMPLETED	2018-10-03	NCT01241500
Astellas	gilteritinib	—	COMPLETED	2018-09-17	NCT02421939
Roche	Chlorambucil	Alkylating Drug [EPC]	COMPLETED	2018-08-17	NCT02242942
Astex Pharmaceuticals, Inc.	SGI-110 (guadecitabine)	—	COMPLETED	2018-05-31	NCT02348489
Johnson & Johnson	Decitabine 20 mg/m^2	—	COMPLETED	2018-01-25	NCT02472145
Traws Pharma, Inc.	rigosertib sodium	—	COMPLETED	2017-06-29	NCT01928537
MedImmune LLC	Moxetumomab pasudotox	—	COMPLETED	2017-05-24	NCT01829711
Novartis	Imatinib	—	COMPLETED	2017-01-30	NCT02272777
Pfizer	Bosutinib	—	COMPLETED	2016-08-11	NCT02130557
Neovii Biotech	US-ATG-F	—	COMPLETED	2015-10-15	NCT01295710
Roche	Cladribine	Purine Antimetabolite [EPC]	COMPLETED	2015-09-14	NCT00718549
Il-Yang Pharm. Co., Ltd.	Imatinib	—	COMPLETED	2015-02	NCT01511289
Boehringer Ingelheim	Volasertib	—	COMPLETED	2014-08-12	NCT01721876
Roche	obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2013-08-31	NCT02053610
Roche	obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2012-08-01	NCT01998880
Roche	obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2012-07-01	NCT01010061
Delta-Fly Pharma, Inc.	DFP-10917	—	TERMINATED	2026-01-07	NCT03926624
Novartis	Sabatolimab	—	TERMINATED	2024-10-02	NCT04266301
Roche	Cytarabine	Nucleoside Metabolic Inhibitor [EPC]	TERMINATED	2020-04-24	NCT02545283
AGC Biologics S.p.A.	—	—	TERMINATED	2019-11-30	NCT00914628
Kiadis Pharma	Donor lymphocyte preparation depleted of host functional alloreactive T-cells	—	TERMINATED	2012-02	NCT00967343
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Liso-cel	—	WITHDRAWN	2031-10-13	NCT06205290
Cristália Produtos Químicos Farmacêuticos Ltda.	propofol	General Anesthetic [EPC]	WITHDRAWN	2011-07	NCT01326078

Showing 100 of 175 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Curis, Inc.	Emavusertib	—	RECRUITING	2026-08	NCT03328078
PersonGen BioTherapeutics (Suzhou) Co., Ltd.	T cell injection targeting CD7 chimeric antigen receptor	—	RECRUITING	2026-10-01	NCT07188610
Aptose Biosciences Inc.	Tuspetinib	—	RECRUITING	2026-11	NCT03850574
Dren Bio	DR-01	—	RECRUITING	2026-12	NCT05475925
Johnson & Johnson	Bleximenib	—	RECRUITING	2027-02-26	NCT04811560
Guangzhou Bio-gene Technology Co., Ltd	BG1805	—	RECRUITING	2027-03	NCT06118788
Vironexis Biotherapeutics Inc.	—	—	RECRUITING	2027-06	NCT06533579
Sumitomo Pharma America, Inc.	Enzomenib	—	RECRUITING	2027-06-30	NCT04988555
Orca Biosystems, Inc.	Orca-T	—	RECRUITING	2027-11	NCT07216443
Juno Therapeutics, a Subsidiary of Celgene	JCAR017 (lisocabtagene maraleucel)	—	RECRUITING	2027-11-26	NCT03331198
Ellipses Pharma	EP0042	—	RECRUITING	2027-12	NCT04581512
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	RECRUITING	2027-12-15	NCT05963074
Syndax Pharmaceuticals	revumenib	—	RECRUITING	2027-12-15	NCT04065399
Incyte Biosciences International Sàrl	Ponatinib	—	RECRUITING	2028-02-01	NCT03934372
Otsuka Medical Devices Co., Ltd. Japan	—	—	RECRUITING	2028-02-28	NCT07075328
Grit Biotechnology	GT719 Injection	—	RECRUITING	2028-04-17	NCT06948981
Miltenyi Biomedicine GmbH	MB-dNPM1-TCR.1	—	RECRUITING	2028-06	NCT06424340
Daiichi Sankyo	Quizartinib High Dose	—	RECRUITING	2028-06-06	NCT06824168
Theradex	Pacritinib	—	RECRUITING	2028-07	NCT07033598
AvenCell Therapeutics, Inc.	Allo-QuadCAR01-T	—	RECRUITING	2029-04-27	NCT07284433
Gyala Therapeutics	CART84	—	RECRUITING	2029-05-31	NCT07471789
Novartis	Asciminib single agent	—	RECRUITING	2033-02-23	NCT07354074
Novartis	Asciminib Pediatric formulation group	—	RECRUITING	2026-06-16	NCT04925479
Ossium Health, Inc.	—	—	RECRUITING	2026-05-31	NCT05589896
Ascentage Pharma Group Inc.	APG-115	—	RECRUITING	2026-05-31	NCT04496349
Delta-Fly Pharma, Inc.	DFP-10917	—	RECRUITING	2026-03-31	NCT06382168
Chongqing Precision Biotech Co., Ltd	CD123 targeted CAR-NK cells	—	RECRUITING	2025-12-31	NCT06006403
Indapta Therapeutics, INC.	IDP-023	—	RECRUITING	2025-12-30	NCT06119685
Cogent Biosciences, Inc.	bezuclastinib	—	RECRUITING	2025-09-19	NCT04996875
Shenzhen TargetRx Co., Ltd.	TGRX-814	—	RECRUITING	2025-02-28	NCT06206174
Beam Therapeutics Inc.	BEAM-201	—	ACTIVE NOT RECRUITING	2026-12	NCT05885464
GeoVax, Inc.	COVID-19 Vaccine	—	ACTIVE NOT RECRUITING	2026-12-31	NCT04977024
OncoVerity, Inc.	Cusatuzumab	—	ACTIVE NOT RECRUITING	2027-01	NCT06384261
Faron Pharmaceuticals Ltd	Bexmarilimab	—	ACTIVE NOT RECRUITING	2027-03	NCT05428969
Novartis	decitabine	Nucleoside Metabolic Inhibitor [EPC]	ACTIVE NOT RECRUITING	2028-02-14	NCT05201066
Kura Oncology, Inc.	Ziftomenib	Menin Inhibitor [EPC]	ACTIVE NOT RECRUITING	2028-10-16	NCT04067336
Eli Lilly	Pirtobrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2030-05	NCT07162181
Takara Bio Inc.	TBI-1501	—	ACTIVE NOT RECRUITING	2035-03-31	NCT03155191
Actuate Therapeutics Inc.	9-ING-41	—	ACTIVE NOT RECRUITING	2026-06	NCT03678883
Molecular Partners AG	MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1	—	ACTIVE NOT RECRUITING	2026-05-29	NCT05673057
Treadwell Therapeutics, Inc	CFI-400945	—	ACTIVE NOT RECRUITING	2026-01	NCT04730258
Bristol-Myers Squibb	CC-486	—	ACTIVE NOT RECRUITING	2025-10-31	NCT05413018
BeiGene	BGB-11417	—	ACTIVE NOT RECRUITING	2025-01-24	NCT05479994
OncoVerity, Inc.	Azacitidine	Nucleoside Metabolic Inhibitor [EPC]	ACTIVE NOT RECRUITING	2023-08-15	NCT04023526
Daiichi Sankyo	Valemetostat Tosylate	—	ACTIVE NOT RECRUITING	2023-05-10	NCT04703192
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2021-07-15	NCT02029443
Bellicum Pharmaceuticals	BPX-501 T cells	—	ACTIVE NOT RECRUITING	2021-05-11	NCT03301168
Bristol-Myers Squibb	AG-120	—	ACTIVE NOT RECRUITING	2018-08-02	NCT02677922
Hebei Senlang Biotechnology Inc., Ltd.	Autologous CD7-targeting CAR T cells	—	NOT YET RECRUITING	2026-09-30	NCT07244380
CARsgen Therapeutics Co., Ltd.	CT071	—	NOT YET RECRUITING	2027-06-15	NCT06333509
Biotroy Therapeutics	BT02	—	NOT YET RECRUITING	2028-01	NCT07107204
Novartis	Asciminib Adult formulation	—	NOT YET RECRUITING	2033-07-18	NCT07387926
Incyte Corporation	Ruxolitinib	—	COMPLETED	2026-03-03	NCT02723994
Abcuro, Inc.	ABC008	—	COMPLETED	2025-08-28	NCT05532722
Constellation Pharmaceuticals	Pelabresib	—	COMPLETED	2025-01-09	NCT02158858
Blueprint Medicines Corporation	Avapritinib	Kinase Inhibitor [EPC]	COMPLETED	2024-12-18	NCT03580655
Hutchmed	Surufatinib	—	COMPLETED	2024-09-06	NCT05077384
Roche	BTCT4465A (Mosunetuzumab) IV	—	COMPLETED	2024-05-21	NCT02500407
Prescient Therapeutics, Ltd.	PTX-200	—	COMPLETED	2023-10-31	NCT02930109
Moleculin Biotech, Inc.	Liposomal Annamycin	—	COMPLETED	2023-08-02	NCT05319587
Novartis	asciminib	—	COMPLETED	2023-05-29	NCT04795427
Eli Lilly	LOXO-305	—	COMPLETED	2023-04-10	NCT04849416
Stemline Therapeutics, Inc.	Tagraxofusp Injection	—	COMPLETED	2023-03-27	NCT02268253
Boehringer Ingelheim	Decitabine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2023-01-16	NCT02632721
Johnson & Johnson	Daratumumab	CD38-directed Cytolytic Antibody [EPC]	COMPLETED	2022-09-22	NCT03384654
OncoVerity, Inc.	ARGX-110	—	COMPLETED	2022-08	NCT03030612
Moleculin Biotech, Inc.	Liposomal Annamycin	—	COMPLETED	2022-02-08	NCT03388749
Novartis	Asciminib add-on	—	COMPLETED	2021-11-08	NCT03578367
AbbVie	Venetoclax	BCL-2 Inhibitor [EPC]	COMPLETED	2021-11-04	NCT03873493
Precision BioSciences, Inc.	Fludarabine	—	COMPLETED	2021-06-24	NCT04030195
Daiichi Sankyo Co., Ltd.	Valemetostat Tosylate	—	COMPLETED	2021-04-24	NCT04102150
Golden Biotechnology Corporation	Antroquinonol	—	COMPLETED	2020-12-31	NCT03823352
Traws Pharma, Inc.	oral rigosertib	—	COMPLETED	2020-12-08	NCT01926587
Kura Oncology, Inc.	Tipifarnib	—	COMPLETED	2020-11-30	NCT02807272
Pharmacyclics LLC.	ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-11-12	NCT02910583
Rhizen Pharmaceuticals SA	Tenalisib	—	COMPLETED	2020-10-02	NCT04204057
Acerta Pharma BV	Acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-07-14	NCT02362035
Bristol-Myers Squibb	CC-122	—	COMPLETED	2020-07-07	NCT02406742
Bioniz Therapeutics	BNZ132-1-40	—	COMPLETED	2020-06-30	NCT03239392
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Efprezimod alfa	—	COMPLETED	2020-06-08	NCT02663622
Bioray Laboratories	CD19 CART	—	COMPLETED	2020-05-06	NCT03232619
SecuraBio	Duvelisib	PI3K-delta/PI3K-gamma	COMPLETED	2020-05-04	NCT02711852
Takeda	Ponatinib	—	COMPLETED	2020-04-29	NCT02467270
Moleculin Biotech, Inc.	Liposomal Annamycin	—	COMPLETED	2020-01-14	NCT03315039
Millennium Pharmaceuticals, Inc.	Azacitidine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2019-09-04	NCT02610777
Beijing Immunochina Medical Science & Technology Co., Ltd.	IM19 CAR-T	—	COMPLETED	2019-05-01	NCT03173417
Novartis	Panobinostat (LBH589)	—	COMPLETED	2019-04-29	NCT00946647
Pfizer	Bosutinib	—	COMPLETED	2019-03-12	NCT03128411
Bristol-Myers Squibb	Durvalumab	Programmed Death Ligand-1 Blocker [EPC]	COMPLETED	2019-03-06	NCT02733042
Bristol-Myers Squibb	Azacitidine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2018-12-31	NCT02775903
MorphoSys AG	Tafasitamab	—	COMPLETED	2018-11	NCT02639910
Bristol-Myers Squibb	Azacitidine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2018-10-10	NCT02450877
Nohla Therapeutics, Inc.	Cyclophosphamide	DNA	COMPLETED	2018-09-18	NCT01690520
Merck	Sotatercept	—	COMPLETED	2018-04-30	NCT01736683
Daiichi Sankyo Co., Ltd.	Quizartinib	—	COMPLETED	2018-03-28	NCT02984995
Bristol-Myers Squibb	Azacitidine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2018-02-28	NCT02447666
GlycoMimetics Incorporated	GMI-1271	—	COMPLETED	2017-12	NCT02306291
MaaT Pharma	Autologous Fecal Microbiota Transplantation	—	COMPLETED	2017-08	NCT02928523
Bristol-Myers Squibb	Lenalidomide	Thalidomide Analog [EPC]	COMPLETED	2017-07-22	NCT02538965
Bristol-Myers Squibb	Dasatinib	ABL kinase/BCR-ABL/EPHA2/FYN/LCK/PDGFRβ/SRC/YES/c-KIT	COMPLETED	2017-05-28	NCT01460160

Showing 100 of 197 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Kura Oncology, Inc.	Ziftomenib	Menin Inhibitor [EPC]	RECRUITING	2026-08	NCT06001788
MacroGenics	MGD024	—	RECRUITING	2026-11	NCT05362773
Newave Pharmaceutical Inc	LP-118	—	RECRUITING	2026-12-31	NCT04771572
Solu Therapeutics, Inc	STX-0712	—	RECRUITING	2026-12-31	NCT06950034
Crossbow Therapeutics, Inc.	CBX-250	—	RECRUITING	2027-01	NCT06994676
Catapult Therapeutics	CAP-100	—	RECRUITING	2027-01	NCT04704323
Shenzhen TargetRx Co., Ltd.	TGRX-1942	—	RECRUITING	2027-02	NCT06484816
Johnson & Johnson	JNJ-90189892	—	RECRUITING	2027-08-05	NCT06651229
Orca Biosystems, Inc.	OrcaGraft (Orca-Q)	—	RECRUITING	2027-12	NCT03802695
Newave Pharmaceutical Inc	LP-168	—	RECRUITING	2027-12-31	NCT04775745
ImmunityBio, Inc.	CD19 t-haNK	—	RECRUITING	2028-12	NCT07556757
Ascentage Pharma Group Inc.	Ascentage Pharma HQP1351 bioavailable inhibitor	—	RECRUITING	2029-12-27	NCT04260022
Kura Oncology, Inc.	Ziftomenib	Menin Inhibitor [EPC]	RECRUITING	2030-04	NCT05735184
Meryx, Inc.	MRX-2843	—	RECRUITING	2026-07	NCT04872478
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	HDM2005	—	RECRUITING	2026-06-24	NCT06615193
Johnson & Johnson	14C-bleximenib	—	RECRUITING	2026-06-14	NCT07295951
BlossomHill Therapeutics	BH-30236	—	RECRUITING	2026-06	NCT06501196
Hangzhou Weben Pharma Co., Ltd	WBC100 QD	—	RECRUITING	2026-06	NCT07014449
Tr1X, Inc.	TRX103	—	RECRUITING	2026-04-15	NCT06462365
Nanjing IASO Biotechnology Co., Ltd.	CAR-GPRC5D	—	RECRUITING	2025-09-01	NCT05759793
Epigenetix, Inc.	EP31670	—	RECRUITING	2025-05	NCT05488548
Johnson & Johnson	Bleximenib	—	ACTIVE NOT RECRUITING	2026-10-30	NCT05453903
OncoVerity, Inc.	Cusatuzumab	—	ACTIVE NOT RECRUITING	2027-05-15	NCT04150887
Johnson & Johnson	JNJ-89853413	—	ACTIVE NOT RECRUITING	2027-07-15	NCT06618001
Kite, A Gilead Company	—	—	ACTIVE NOT RECRUITING	2026-07	NCT06539338
3D Medicines	3D189	—	ACTIVE NOT RECRUITING	2026-06	NCT05320809
Johnson & Johnson	JNJ-80948543	—	ACTIVE NOT RECRUITING	2025-10-31	NCT05424822
Foghorn Therapeutics Inc.	FHD-286	—	ACTIVE NOT RECRUITING	2025-09	NCT04891757
Orca Biosystems, Inc.	Orca-T	—	ACTIVE NOT RECRUITING	2025-04-30	NCT04013685
Eli Lilly	LY3410738	—	ACTIVE NOT RECRUITING	2023-07-03	NCT04603001
Eli Lilly	LOXO-338	—	ACTIVE NOT RECRUITING	2023-06-14	NCT05024045
Bellicum Pharmaceuticals	BPX-501 T cells	—	ACTIVE NOT RECRUITING	2022-09	NCT03459170
Bellicum Pharmaceuticals	BPX-501	—	ACTIVE NOT RECRUITING	2020-01-14	NCT02477878
Guangzhou Bio-gene Technology Co., Ltd	BG1805	—	NOT YET RECRUITING	2027-04	NCT06347458
Laguna Biotherapeutics, Inc.	QUAIL-100	—	NOT YET RECRUITING	2028-06	NCT07573111
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB3909 tablets	—	NOT YET RECRUITING	2025-12	NCT06211751
Newave Pharmaceutical Inc	LP-108	—	COMPLETED	2025-12-19	NCT04139434
Johnson & Johnson	JNJ-75348780	—	COMPLETED	2025-09-09	NCT04540796
Johnson & Johnson	JNJ-74856665	—	COMPLETED	2025-08-25	NCT04609826
SDK Therapeutics, Inc.	Treatment A: Arsenic Trioxide (ATO) Intravenous	—	COMPLETED	2025-06-25	NCT06882031
Prelude Therapeutics	PRT2527	—	COMPLETED	2025-06-12	NCT05665530
Johnson & Johnson	JNJ-64264681	—	COMPLETED	2025-05-28	NCT04210219
Johnson & Johnson	JNJ-67856633	—	COMPLETED	2025-05-22	NCT03900598
Kymera Therapeutics, Inc.	KT-333	—	COMPLETED	2025-03-03	NCT05225584
Johnson & Johnson	JNJ-67856633	—	COMPLETED	2025-02-13	NCT04876092
AbbVie	rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2025-02-07	NCT00788684
Syndax Pharmaceuticals	Revumenib	—	COMPLETED	2024-11-18	NCT05406817
Syndax Pharmaceuticals	Revumenib	—	COMPLETED	2024-07-29	NCT05326516
Dialectic Therapeutics, Inc	DT2216	—	COMPLETED	2024-06-30	NCT04886622
Chongqing Peg-Bio Biopharm Co., Ltd.	PD5K3	—	COMPLETED	2024-05-20	NCT06527781
Bristol-Myers Squibb	CC-486	—	COMPLETED	2024-01-08	NCT04887857
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Zilovertamab vedotin	—	COMPLETED	2023-12-18	NCT03833180
Bristol-Myers Squibb	enasidenib	—	COMPLETED	2023-09-22	NCT03720366
Boryung Pharmaceutical Co., Ltd	BR101801 (Phase Ia)	—	COMPLETED	2023-09-21	NCT04018248
Novartis	Decitabine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2023-09-08	NCT03066648
Innovent Biologics (Suzhou) Co. Ltd.	IBI322	—	COMPLETED	2023-08-15	NCT04795128
Epizyme, Inc.	Tazemetostat	—	COMPLETED	2023-04-03	NCT04537715
Precision BioSciences, Inc.	—	—	COMPLETED	2022-12-22	NCT04649112
Prelude Therapeutics	PRT543	—	COMPLETED	2022-11-16	NCT03886831
Blueprint Medicines Corporation	Avapritinib	Kinase Inhibitor [EPC]	COMPLETED	2022-10-05	NCT02561988
Celldex Therapeutics	CDX-1140	—	COMPLETED	2022-09-13	NCT03329950
Johnson & Johnson	JNJ-67571244	—	COMPLETED	2022-03-26	NCT03915379
Nanexa AB	NEX-18a injection	—	COMPLETED	2022-02-10	NCT05048498
Millennium Pharmaceuticals, Inc.	Pevonedistat 25 mg/m^2	—	COMPLETED	2022-01-25	NCT02782468
AstraZeneca	AZD4573	—	COMPLETED	2021-09-30	NCT03263637
Acerta Pharma BV	acalabrutinib	Kinase Inhibitor [EPC]	COMPLETED	2021-08-20	NCT02296918
OncoVerity, Inc.	Cusatuzumab	—	COMPLETED	2021-07-19	NCT04241549
Jazz Pharmaceuticals	CPX-351	—	COMPLETED	2021-05-26	NCT03555955
Johnson & Johnson	JNJ-63709178	—	COMPLETED	2021-03-26	NCT02715011
Takeda	Azacitidine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2021-03-19	NCT03814005
Angiocrine Bioscience	Unmanipulated Umbilical Cord Blood (UCB)	—	COMPLETED	2020-12-21	NCT03483324
BeiGene	Zanubrutinib	Kinase Inhibitor [EPC]	COMPLETED	2020-12-18	NCT02795182
Roche	Cobimetinib	—	COMPLETED	2020-12-10	NCT02670044
miRagen Therapeutics, Inc.	Cobomarsen	—	COMPLETED	2020-10-06	NCT02580552
Telios Pharma, Inc.	TL-895	—	COMPLETED	2020-09-22	NCT04419623
OrphAI Therapeutics	LAM-002A	—	COMPLETED	2020-03-09	NCT02594384
Humanigen, Inc.	lenzilumab	—	COMPLETED	2020-02	NCT02546284
Pfizer	PF-04449913 (Glasdegib)	—	COMPLETED	2020-01-29	NCT02367456
Roche	DCLL9718S	—	COMPLETED	2019-07-16	NCT03298516
Astex Pharmaceuticals, Inc.	ASTX727 + Day 2 Food	—	COMPLETED	2019-06-14	NCT03813186
Boehringer Ingelheim	BI 836826	—	COMPLETED	2019-06-03	NCT02759016
Bristol-Myers Squibb	CC-292	—	COMPLETED	2019-01-23	NCT01732861
Sumitomo Pharma America, Inc.	BBI608	—	COMPLETED	2018-12-14	NCT02352558
Bayer	BAY1436032	—	COMPLETED	2018-12-06	NCT03127735
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	CTTQ Dasatinib tablet	—	COMPLETED	2018-10-03	NCT05640804
Janssen Pharmaceutical K.K.	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2018-08-20	NCT02556892
Johnson & Johnson	Ibrutinib	Kinase Inhibitor [EPC]	COMPLETED	2018-07-17	NCT03301207
Bristol-Myers Squibb	CC-486	—	COMPLETED	2018-06-11	NCT02223052
Millennium Pharmaceuticals, Inc.	Sapanisertib	—	COMPLETED	2018-05-31	NCT02412722
Boehringer Ingelheim	BI 836858	—	COMPLETED	2018-05-21	NCT01690624
Roche	Obinutuzumab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2018-05-21	NCT01685892
Bristol-Myers Squibb	BMS-906024	—	COMPLETED	2018-02-07	NCT01363817
Boehringer Ingelheim	BI 836826	—	COMPLETED	2017-05-30	NCT01296932
Seagen Inc.	SGN-CD19A	—	COMPLETED	2017-05-30	NCT01786096
Bayer	Atuveciclib, BAY1143572	—	COMPLETED	2016-09-14	NCT02345382
Roche	RO5503781 MBP	—	COMPLETED	2016-06	NCT01773408
Epizyme, Inc.	EPZ-5676	—	COMPLETED	2016-05	NCT02141828
Bristol-Myers Squibb	azacitidine	Nucleoside Metabolic Inhibitor [EPC]	COMPLETED	2016-04-06	NCT00761722
Seagen Inc.	HMA	—	COMPLETED	2016-03-18	NCT01902329
Bristol-Myers Squibb	CC-292	—	COMPLETED	2015-12	NCT01744626

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Leukemia

RET (12) FLT3 (10) FGFR (8) BCR-ABL (7) BTK (5) PDGFR gene re-arrangement (2)

Novel Leukemia Drugs by Company (New molecular entities)

1 company has an FDA-approved novel drug for Leukemia.

Sanofi 1 drug

ELITEK

RASBURICASE

BLA 2002

Reformulations (9 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.